SCHEMBL2276276

SCHEMBL2276276

O=C(O)c1ccc(-c2ccccc2)cc1NC(=O)c1cccnc1N1CCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
TSHR P16473 1/20 0.52
HSD17B10 Q99714 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
SCN10A Q9Y5Y9 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
ACLY P53396 5/20 0.49
GAA P10253 1/20 0.48
KIF18A Q8NI77 1/20 0.47
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HDAC1 Q13547 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270252 0.84 TSHR (0.62) ALDH1A1KMT2AMEN1TSHRHSD17B10
SCHEMBL14428686 0.84 L3MBTL1 (0.51) ALDH1A1KMT2AMEN1TSHRHSD17B10
SCHEMBL2278079 0.79 HDAC2 (0.63) ACLYHDAC1DHODH
SCHEMBL1317484 0.77 ACLY (0.50) ALDH1A1KMT2AMEN1ACLYKDM4E
SCHEMBL3309889 0.77 KMT2A (0.70) ALDH1A1KMT2AMEN1TSHRHSD17B10
SCHEMBL1315669 0.76 ACLY (0.49) ACLYHDAC1DHODH
SCHEMBL16217083 0.76 ALDH1A1 (0.65) ALDH1A1KMT2AMEN1TSHRHSD17B10
SCHEMBL14758381 0.76 ALDH1A1 (0.62) ALDH1A1KMT2AMEN1TSHRHSD17B10
SCHEMBL11399275 0.75 KMT2A (0.68) ALDH1A1KMT2AMEN1TSHRHSD17B10
SCHEMBL17746092 0.75 KMT2A (0.68) ALDH1A1KMT2AMEN1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ALDH1A1 645/4885KMT2A 1669/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.